Article
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.
Oncotarget - 1 Dec 2012
Robert Guillaume, Jullian Valérie, Jacquel Arnaud, Ginet Clémence, Dufies Maeva, Torino Stephanie, Pottier Anaïs, Peyrade Frederic, Tartare-Deckert Sophie, Bourdy Geneviève, Deharo Eric, Auberger Patrick
Abstract excerpt
Simalikalactone E (SkE) is a quassinoid extracted from a widely used Amazonian antimalarial remedy. Although SkE has previously been shown to have cytostatic and/or cytotoxic activities in some tumor cell lines, its mechanism of action has not yet been characterized. We show here that SkE in the high nanomolar range inhibited the growth of various leukemic and solid tumor cell lines. Importantly, SkE was highly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.